Form 4 for SLXN Silexion Therapeutics Corp

Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-20 · accession 0001178913-26-000594 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2026-02-23	2026-02-20	SLXN	Lushi Avner	Dir	A - Grant	$0.00	+9,091	25.4K	+56%	$0
DI	2026-02-23	2026-02-20	SLXN	Lushi Avner	Dir	A - Grant	$0.00	+10.7K	10.7K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-02-20	A	A	9,091	$0.00	25,399	I By Guangzhou Sino-Israel Biotech Fund	—	—	(F2) The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
2	Derivative	Stock Option (right to buy ordinary shares)	2026-02-20	A	A	10,685	$0.00	10,685	I By Guangzhou Sino-Israel Biotech Fund	$1.65 · 2027-02-12 to 2036-02-12	10,685 Ordinary Shares	(F2) The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this row as a result of his serving as a Managing Partner and CEO of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein. (F4) The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.